PTGX vs SYRE
Protagonist Therapeutics, Inc. vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
64
Buy
VS
SYRE
Spyre Therapeutics, Inc.
68
Buy
| Metric | PTGX | SYRE |
|---|
| AI Score |
64
|
68
|
| Price |
$151.99
|
$104.13
|
| P/E Ratio |
121.74×
|
-52.69×
|
| ROE |
-21.2%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
0.0%
|
| Debt / Equity |
0.01×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
68.1
|
53.3
|
| Beta |
1.794
|
3.026
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for PTGX versus SYRE.
SYRE leads by 4 points.
SYRE scores 68/100 (Buy) versus PTGX at 64/100 (Buy).
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical
SYRE Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical